Hepatocellular Carcinoma Serum Markers

**Indications for Ordering**

- Alpha fetoprotein (AFP), total and L3 percent
  - Surveillance in conjunction with abdominal ultrasound for early detection of hepatocellular carcinoma (HCC) in high-risk groups
  - Posttreatment monitoring when pretreatment concentration was elevated
- Des-gamma-carboxy prothrombin (DCP)
  - Surveillance in conjunction with abdominal ultrasound for early detection of HCC in high-risk groups
  - May be used in monitoring if pretreatment levels were elevated

**Test Description**

- Alpha Fetoprotein, Total and L3 Percent
  - Quantitative liquid chromatography/immunoassay
  - Alpha fetoprotein L3 isoform (AFP-L3%) is calculated as a percentage of AFP-L3 in the total AFP concentration
- Des-gamma-carboxy Prothrombin
  - Quantitative liquid chromatography/immunoassay

**Tests to Consider**

**Primary tests**
- Alpha Fetoprotein, Total and L3 Percent 0081208
  - Surveillance and monitoring of HCC
- Des-gamma-carboxy Prothrombin 0081312
  - Surveillance and monitoring of HCC

**Related tests**
- Alpha Fetoprotein, Serum (Tumor Marker) 0080428
  - Surveillance and monitoring of HCC
  - Less specific than test that includes AFP-L3 isoform
- Hepatocellular Carcinoma Tumor Marker Panel 0081326
  - Acceptable panel for surveillance and monitoring of HCC
  - Includes AFP total, AFP-L3%, and DCP

**Disease Overview**

**Prevalence and/or incidence**
- 4-11/100,000 (U.S. and Europe)
- >26,000 new cases per year (NCCN 2011)

**Screening/detection**

- Disease is often discovered at late stage due to nonspecific symptoms
  - Poor prognosis at this point
- Possible role for surveillance of high-risk individuals using combined serum marker testing and abdominal ultrasound to detect earlier disease

**Biology**

- **AFP-L3**
  - AFP has 3 isoforms – L1, L2, L3
  - L3 isoform is expressed by malignant hepatocytes
  - L3 isoform has highest affinity for lectin from *Lens culinaris*, which makes it possible to differentiate L3 from other isoforms
- **DCP**
  - Also referred to as PIVKA-II (protein induced by vitamin K absence or antagonist II)
  - Nonfunctional prothrombin
  - Results from lack of carboxylation of 10 glutamic acid residues
  - Vitamin K dependent carboxylase, which catalyzes this reaction in many HCCs, is absent

**Test Interpretation**

**Sensitivity/specificity**

- Clinical sensitivity/specificity
  -AFP-L3%
    - L3% ≥10%
      - Relative risk (RR) – 43.3% (95% CI: 31.4-55.4%)
    - L3% <10%
      - RR – 4.1% (95% CI: 1.6-6.6%)
  - DCP
    - DCP ≥7.5
      - RR – 36.5% (95% CI: 23.5-49.6%)
    - DCP <7.5
      - RR – 7.6% (95% CI: 4.4-10.8%)
- Analytical sensitivity
  - AFP and DCP – 0.1 ng/mL
- Analytical specificity – none known

**Results**

- Normal cutoffs
  - AFP – 0-15 ng/mL
  - AFP-L3% – 0-9.9%
  - DCP – 0-7.4 ng/mL
Limitations

- Not all HCCs secrete AFP and/or DCP
  - Test is not useful for monitoring if pretreatment levels were not elevated
- False-positive result may occur in the following clinical contexts
  - AFP-L3%
    - Pregnancy
    - Age <1 year
    - Acute fulminant hepatitis
    - Cirrhosis
  - DCP
    - Obstructive jaundice
    - Intrahepatic cholestasis
    - Drugs (eg, warfarin)